how to keep weight off after stopping glp 1 medication Maintain Loss GLP-1 – KETO-MOJO Patient Handout: Strategies for Keeping

Improved metabolic flexibility Obesity and type 2 diabetes are commonly associated with impaired metabolic flexibility, meaning the body has difficulty switching efficiently between glucose and fat oxidation

Heres what scientists know and dont know about the effect of tea on body weight

Choose Mini for hydration + nausea relief, Plus for deeper nutrient replenishment, and Max for the strongest antioxidant recovery support

While GLP-1 receptor agonists like tirzepatide and semaglutide have revolutionized obesity treatment, emerging evidence suggests that strategic compounding with complementary agents may enhance therapeutic outcomes

CagriSema vs Comparators Feature Receptor targets CagriSema Amylin/calcitonin + GLP-1 Tirzepatide (Zepbound) GIP + GLP-1 Semaglutide alone (Wegovy) GLP-1 Cagrilintide alone Amylin/calcitonin (DACRA) Feature Dosing frequency CagriSema Once weekly Tirzepatide (Zepbound) Once weekly Semaglutide alone (Wegovy) Once weekly Cagrilintide alone Once weekly Feature Maintenance dose CagriSema 2.4 mg + 2.4 mg Tirzepatide (Zepbound) Up to 15 mg Semaglutide alone (Wegovy) 2.4 mg Cagrilintide alone 2.4 mg (in REDEFINE arms) Feature Headline weight loss CagriSema 20.4% at 68 wks (REDEFINE 1, treatment-policy) Tirzepatide (Zepbound) Up to 22.5% at 72 wks (SURMOUNT-1, 15 mg arm) Semaglutide alone (Wegovy) 14.9% at 68 wks (REDEFINE 1 reference arm) Cagrilintide alone 11.5% at 68 wks (REDEFINE 1 reference arm) Feature FDA status (June 2026) CagriSema NDA filed Dec 2025